title: B-Cell Disorders and Curcumin.
abstract: Clinical studies with patients with early hematological malignancies (ie, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or stage 0/1 chronic lymphocytic leukemia) suggest that early intervention with curcumin, derived from the spice turmeric, may lead to prolonged survival and delay in progressive disease in some of these patients.
authors.affiliation: 1 St George Hospital, Sydney, New South Wales, Australia.
authors.forename: Terry
authors.initials: T
authors.lastname: Golombick
authors.affiliation: 1 St George Hospital, Sydney, New South Wales, Australia.
authors.forename: Terrence H
authors.initials: TH
authors.lastname: Diamond
authors.affiliation: 2 University of Wollongong, Wollongong, NSW, Australia.
authors.forename: Arumugam
authors.initials: A
authors.lastname: Manoharan
authors.affiliation: 2 University of Wollongong, Wollongong, NSW, Australia.
authors.forename: Rajeev
authors.initials: R
authors.lastname: Ramakrishna
mesh_terms: D001402:B-Lymphocytes / Q000187:drug effects* / Q000473:pathology; D030024:Curcuma / Q000737:chemistry; D003474:Curcumin / Q000494:pharmacology*; D018450:Disease Progression; D006402:Hematologic Diseases / Q000188:drug therapy*; D006801:Humans
chemical_list: D003474:Curcumin
keywords: curcumin; integrative medicine; monoclonal gammopathy of undetermined significance; smoldering myeloma; stage 0/1 chronic lymphocytic leukemia